CN113710664B - Jak1选择性激酶抑制剂 - Google Patents

Jak1选择性激酶抑制剂 Download PDF

Info

Publication number
CN113710664B
CN113710664B CN202080029899.3A CN202080029899A CN113710664B CN 113710664 B CN113710664 B CN 113710664B CN 202080029899 A CN202080029899 A CN 202080029899A CN 113710664 B CN113710664 B CN 113710664B
Authority
CN
China
Prior art keywords
methoxy
indol
amino
methylpiperazin
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080029899.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN113710664A (zh
Inventor
齐长河
徐汉忠
曾庆北
杨振帆
张小林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dizhe Jiangsu Pharmaceutical Co ltd
Dizhe Shanghai Pharmaceutical Co ltd
Original Assignee
Dizhe Shanghai Pharmaceutical Co ltd
Dizhe Jiangsu Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizhe Shanghai Pharmaceutical Co ltd, Dizhe Jiangsu Pharmaceutical Co ltd filed Critical Dizhe Shanghai Pharmaceutical Co ltd
Publication of CN113710664A publication Critical patent/CN113710664A/zh
Application granted granted Critical
Publication of CN113710664B publication Critical patent/CN113710664B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080029899.3A 2019-04-19 2020-04-17 Jak1选择性激酶抑制剂 Active CN113710664B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019083376 2019-04-19
CNPCT/CN2019/083376 2019-04-19
PCT/CN2020/085338 WO2020211839A1 (en) 2019-04-19 2020-04-17 Jak1 selective kinase inhibitor

Publications (2)

Publication Number Publication Date
CN113710664A CN113710664A (zh) 2021-11-26
CN113710664B true CN113710664B (zh) 2024-01-26

Family

ID=72837031

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080029899.3A Active CN113710664B (zh) 2019-04-19 2020-04-17 Jak1选择性激酶抑制剂

Country Status (15)

Country Link
US (1) US20220220096A1 (enExample)
EP (1) EP3956322B1 (enExample)
JP (1) JP7555959B2 (enExample)
KR (1) KR20220003537A (enExample)
CN (1) CN113710664B (enExample)
AR (1) AR118729A1 (enExample)
AU (1) AU2020258619B2 (enExample)
BR (1) BR112021020964A2 (enExample)
CA (1) CA3134174A1 (enExample)
DK (1) DK3956322T3 (enExample)
ES (1) ES3031576T3 (enExample)
MX (1) MX2021012749A (enExample)
PT (1) PT3956322T (enExample)
TW (1) TW202104215A (enExample)
WO (1) WO2020211839A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7613778B2 (ja) * 2020-11-26 2025-01-15 科輝智薬（深▲セン▼）新薬研究中心有限公司 アミド化合物、医薬組成物およびその使用
CN114380806B (zh) * 2022-03-24 2022-06-10 中国药科大学 2-氨基-4-吲哚基嘧啶类化合物及其制备方法与应用
US12240836B2 (en) * 2022-07-05 2025-03-04 Dong-A St Co., Ltd. Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof
EP4554931A1 (en) * 2022-07-12 2025-05-21 Adama Makhteshim Ltd. Process for preparing substituted benzamides
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法
GB202403369D0 (en) 2024-03-08 2024-04-24 Astrazeneca Ab Process and intermediates for the production of a jak1 inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018134213A1 (en) * 2017-01-17 2018-07-26 Astrazeneca Ab Jak1 selective inhibitors
CN108368091A (zh) * 2015-09-25 2018-08-03 迪哲（江苏）医药有限公司 用于抑制jak的化合物和方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9198900B2 (en) * 2011-11-10 2015-12-01 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Treatment of peritoneal injury using JAK inhibitors
WO2020057669A1 (zh) * 2018-09-21 2020-03-26 上海轶诺药业有限公司 一类具有激酶抑制活性的芳香杂环类化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108368091A (zh) * 2015-09-25 2018-08-03 迪哲（江苏）医药有限公司 用于抑制jak的化合物和方法
WO2018134213A1 (en) * 2017-01-17 2018-07-26 Astrazeneca Ab Jak1 selective inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Discovery of (2R)‑N‑[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]‑1H‑indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor;Qibin Su;J. Med. Chem.;第63卷;4517−4527 *

Also Published As

Publication number Publication date
ES3031576T3 (en) 2025-07-09
EP3956322A1 (en) 2022-02-23
US20220220096A1 (en) 2022-07-14
PT3956322T (pt) 2025-06-04
EP3956322B1 (en) 2025-05-14
KR20220003537A (ko) 2022-01-10
WO2020211839A1 (en) 2020-10-22
BR112021020964A2 (pt) 2021-12-14
JP2022529061A (ja) 2022-06-16
CA3134174A1 (en) 2020-10-22
CN113710664A (zh) 2021-11-26
AR118729A1 (es) 2021-10-27
TW202104215A (zh) 2021-02-01
DK3956322T3 (da) 2025-06-16
JP7555959B2 (ja) 2024-09-25
AU2020258619B2 (en) 2025-10-23
MX2021012749A (es) 2021-11-18
EP3956322A4 (en) 2023-05-03
AU2020258619A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
CN113710664B (zh) Jak1选择性激酶抑制剂
US10556908B2 (en) Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US10640503B2 (en) Imidazopyridines and imidazopyrazines as LSD1 inhibitors
US10968221B2 (en) Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
TWI704152B (zh) 作為ｊａｋ激酶抑制劑之萘啶化合物
JP6800969B2 (ja) 呼吸器疾患の処置のためのｊａｋキナーゼ阻害剤化合物
ES2873001T3 (es) Heterociclaminas como inhibidores de PI3K
US20120208799A1 (en) Compounds
JP2017515836A (ja) ピラゾロピリジンおよびピラゾロピリミジン
JP2015533181A (ja) Ｐｉ３ｋ阻害剤としてのピロロトリアジノン誘導体
US20240209001A1 (en) Heterocyclic derivatives as janus kinase inhibitors
RU2818002C2 (ru) Селективный ингибитор киназы JAK1
HK40055987A (en) Jak1 selective kinase inhibitor
HK40055987B (zh) Jak1选择性激酶抑制剂
US20240092791A1 (en) Dihydrofuropyridine derivatives as rho-kinase inhibitors
HK1234392A1 (en) Pyrazolopyridines and pyrazolopyrimidines

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40055987

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20221230

Address after: 199 Liangjing Road, Zhangjiang hi tech park, Pudong New Area, Shanghai 201203

Applicant after: Dizhe (Jiangsu) Pharmaceutical Co.,Ltd.

Applicant after: Dizhe (Shanghai) Pharmaceutical Co.,Ltd.

Address before: 199 Liangjing Road, Zhangjiang hi tech park, Pudong New Area, Shanghai 201203

Applicant before: Dizhe (Jiangsu) Pharmaceutical Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant